Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of Eribulin ORA for treatment of cancer

Trial Profile

A phase 1 study of Eribulin ORA for treatment of cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2018 New trial record
    • 29 Oct 2018 According to an media release, the FDA has allowed the IND application for the oral formulation of Eribulin. The company expects to initiate this study in first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top